###begin article-title 0
###xml 42 50 <span type="species:ncbi:9606">Patients</span>
Leukotriene-related Gene Polymorphisms in Patients with Aspirin-intolerant Urticaria and Aspirin-intolerant Asthma: Differing Contributions of ALOX5 Polymorphism in Korean Population
###end article-title 0
###begin p 1
###xml 849 854 849 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5</italic>
###xml 954 955 954 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1100 1101 1100 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 293 301 <span type="species:ncbi:9606">patients</span>
The pathogenesis of aspirin (acetylsalicylic acid, ASA)-intolerant urticaria (AIU) is still poorly understood but it has recently been suggested that it is associated with the overproduction of leukotriene (LT). This is supported by evidence that cyclooxygenase 2 inhibitor is given safely to patients with AIU. The present study was designed to investigate the role of genetic polymorphism of LT related genes in the pathogenesis of AIU via a case-control study. We screened single nucleotide polymorphisms (SNPs) in genes encoding enzymes involved in leukotriene synthesis in the Korean population with AIU (n=101), ASA-intolerant asthma (AIA, n=95) and normal healthy controls (n=123). Genotype was determined by primer extension reactions using the SNapShot ddNTP primer extension kit. Among 8 SNPs of four LT related genes, the polymorphism of ALOX5 at positions of -1708 G>A showed significant difference in genotype frequency between AIU and AIA (p=0.01). Furthermore, there were significant differences observed in the frequencies of two ALOX5 haplotypes between the AIU group and AIA group (p<0.05). However, there were no differences in allele, genotype, or haplotype frequencies of ALOX5 between the AIU group and the normal control group. These results suggested that ALOX5 has a differing contribution in two major clinical pathogenesis related to ASA-sensitivity.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 257 258 257 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 88 96 <span type="species:ncbi:9606">Patients</span>
Aspirin (acetylsalicylic acid, ASA) sensitivity results in distinct clinical syndromes. Patients sensitive to ASA usually develop either a respiratory syndrome (ASA-intolerant asthma, AIA) or a cutaneous syndrome (ASA-intolerant urticaria/angioedema, AIU) (1, 2). ASA is also an occasional cause of anaphylaxis (3).
###end p 3
###begin p 4
###xml 417 418 417 418 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 505 506 505 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 508 509 508 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 585 586 585 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 588 589 588 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 442 450 <span type="species:ncbi:9606">patients</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
The pathogenesis of ASA sensitivity most likely involves inhibition of cyclooxygenase by ASA or other nonsteroidal anti-inflammatory drugs (NSAIDs) resulting in an enhanced production of leukotrienes (LTs), potent inflammatory mediators synthesized from arachidonic acid through a sequential pathway. It is widely recognized that LT biosynthesis is associated with the development and progression of AIA. Urinary LT E4 excretion is higher in patients sensitive to ASA than in patients insensitive to ASA (4, 5). Drugs that inhibit the synthesis of LT have clinical efficacy in asthma (6, 7).
###end p 4
###begin p 5
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 389 390 389 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 513 514 513 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 709 711 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 987 989 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 990 992 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1097 1099 1097 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 1101 1103 1101 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1163 1164 1163 1164 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1251 1252 1251 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
###xml 283 291 <span type="species:ncbi:9606">patients</span>
###xml 1078 1086 <span type="species:ncbi:9606">patients</span>
###xml 1109 1117 <span type="species:ncbi:9606">patients</span>
###xml 1188 1196 <span type="species:ncbi:9606">patients</span>
###xml 1222 1230 <span type="species:ncbi:9606">patients</span>
In contrast to AIA, the study of the cutaneous reaction resulting from ASA sensitivity has not yet led to understanding of the mechanism underlying this reaction. Many patients with chronic urticaria exhibit increased wheal and swelling after intake of ASA (2, 8). The proportion of patients with chronic urticaria who develop exacerbation after ASA administration ranges from 20% to 30% (1), whereas ASA administration causes urticaria and/or angioedema in a percentage ranging from 1% to 6% of normal subjects (9). The mechanisms of such hypersensitivity to ASA are still poorly understood. It has been postulated that ASA sensitivity may be caused by a mechanism with increased production of cysteinyl-LT (10) as the pathogenesis of AIA. This suggestion is strengthened by several reports that antihistamine, histamine receptor 1 antagonist, may not be sufficient as a monotherapy in urticaria sensitive to ASA and LT receptor antagonist (LTRA) may be effective in chronic urticaria (11-14). It has been reported that cyclooxygenase-2 (COX2) inhibitor may be given safely to patients with AIU (15, 16). In patients with chronic urticaria, baseline urinary LT E4 excretion is higher in patients sensitive to ASA than in patients insensitive to ASA (1). These studies support the hypothesis that overproduction of LT may be important in chronic urticaria.
###end p 5
###begin p 6
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
Although there is no clear evidence of the involvement of LT in AIU and/or angioedema, it has been proposed that LTs may participate in the pathogenesis of urticaria and angioedema in a similar mechanism to that of AIA. We (17) and others (18, 19) have previously shown that polymorphism in LT related genes is associated with AIA. Therefore, there is a rationale to investigate the genetic polymorphisms of candidate genes related with LT production in AIU and/or angioedema.
###end p 6
###begin p 7
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5</italic>
###xml 160 167 160 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5AP</italic>
###xml 205 210 205 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTGS2</italic>
###xml 234 239 234 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTC4S</italic>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
In this study, we investigated the genetic polymorphism in 8 candidate single nucleotide polymorphisms (SNPs) of four LT related genes, ALOX5 (5-lipoxygenase), ALOX5AP (5-lipoxygenase activating protein), PTGS2 (cyclooxygenase 2) and LTC4S (LTC4 synthase), in patients with AIU compared to AIA and a normal healthy control group recruited from a Korean population.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Study subjects
###end title 9
###begin p 10
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1860 1890 1860 1890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Dermatophagoides pteronyssinus</italic>
###xml 1892 1916 1892 1916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Dermatophagoides farinae</italic>
###xml 2014 2025 2014 2025 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Aspergillus</italic>
###xml 2027 2037 2027 2037 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alternaria</italic>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 193 201 <span type="species:ncbi:9606">patients</span>
###xml 491 499 <span type="species:ncbi:9606">patients</span>
###xml 788 796 <span type="species:ncbi:9606">patients</span>
###xml 1240 1248 <span type="species:ncbi:9606">Patients</span>
###xml 1515 1523 <span type="species:ncbi:9606">patients</span>
###xml 1605 1613 <span type="species:ncbi:9606">patients</span>
###xml 1860 1890 <span type="species:ncbi:6956">Dermatophagoides pteronyssinus</span>
###xml 1892 1916 <span type="species:ncbi:6954">Dermatophagoides farinae</span>
###xml 1918 1921 <span type="species:ncbi:9685">cat</span>
###xml 1923 1926 <span type="species:ncbi:9615">dog</span>
###xml 1982 1989 <span type="species:ncbi:4220">mugwort</span>
One hundred one patients with urticaria sensitive to both ASA and NSAIDs (46 male subjects; mean age: 34.2 yr; 31 patients had underlying chronic urticaria with more than 6 weeks duration), 95 patients with ASA-intolerant asthma (35 male subjects, mean age: 42.3 yr), and 123 normal healthy controls (NC) enrolled from the Department of Allergy and Rheumatology, Ajou University Hospital, Suwon, Korea were enrolled in the study. In this study, ASA-intolerant urticaria group was defined as patients having a certain history of urticaria/angioedema development after the ingestion of more than two kinds of NSAIDs and positive responders on oral ASA challenge test (classified as cross reacting group by Sanchez-Borges et al. (20)). Also NSAIDs sensitivity could be confirmed because the patients visited our Allergy Clinic or emergency room presenting current urticaria/angioedema after taking NSAIDs. In order to exclude a single ASA-intolerant urticaria, we performed skin prick test with 10 mg/mL of lysine-ASA (L-ASA) and none of them had positive skin prick test. ASA-intolerant asthma was diagnosed by a positive result to L-ASA bronchoprovocation testing and they had no history of drug allergies presenting as skin manifestations. Patients having both AIA and AIU were excluded in this study. 123 normal controls, who had non-atopy, no personal and family history of allergic diseases, and no past history of ASA and other drug hypersensitivity, were recruited from the general population. Seventy (77.8%) patients among the ASA-intolerant urticaria group and 35 (43.8%) in ASA-intolerant asthma patients were atopic. All subjects provided informed consent and the protocol used were approved by the ethics committee of Ajou University Hospital, Suwon, Korea. Skin prick tests were performed with 12 common aeroallergens (Bencard Co., U.K.) including Dermatophagoides pteronyssinus, Dermatophagoides farinae, cat, dog, cockroach, tree pollen mixture, grass pollen mixture, mugwort, ragweed, Hop Japanese, Aspergillus, Alternaria, with histamine and saline controls.
###end p 10
###begin title 11
Oral ASA challenge and L-ASA bronchoprovocation tests
###end title 11
###begin p 12
###xml 403 404 403 404 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1074 1075 1072 1073 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1202 1203 1200 1201 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1256 1257 1254 1255 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
All medications, including theophyllines, beta-2 agonists, LT receptor antagonist, anti-histamine and steroids were stopped 72 hr before the procedure. After the placebo challenge, 500 mg of ASA in a tablet was orally administered, and patients were observed for 4 hr with monitoring of urticaria and changes of lung functions every 30 min. Appearance of urticaria within 4 hr without any changes of FEV1 was considered as a positive result. L-ASA bronchoprovocation test was performed according to the modified method as previously described (17, 21). The test solutions were delivered by a DeVilbiss 646 nebulizer (DeVilbiss Co., Somerset, Penn., U.S.A.) and connected to a compressed air source (5 L/min). L-ASA powder (Althargyl(R), Arthromedica, Swiss) that contained 900 mg L-ASA with 100 mg aminoacetic acid was diluted in normal saline to produce a stock solution of 300 mg/mL. A placebo solution of normal saline was used as a control. Subjects inhaled the aerosol via a mouthpiece during normal tidal breathing. The L-ASA solution was inhaled every 30 min. The FEV1 and maximum mid expiratory flow (MMEF) are measured at 10 and 30 min after each dose. The provocation was stopped when the FEV1 has decreased 20% or more from the baseline. The FEV1 and MMEF after the last dose were measured at 10, 30, 60 min, and then hourly for 7 hr.
###end p 12
###begin title 13
Genomic DNA preparation and SNP genotyping
###end title 13
###begin p 14
###xml 274 279 265 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5</italic>
###xml 281 288 272 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5AP</italic>
###xml 290 295 281 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTGS2</italic>
###xml 300 305 291 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTC4S</italic>
###xml 431 438 422 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 547 548 538 539 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 605 608 592 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq</italic>
###xml 775 777 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1226 1228 1213 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
Peripheral blood samples (10 mL) were collected from study subjects. Genomic DNA was extracted using a G-DEXtrade mark for Blood Genomic DNA Extraction Kit (iNtRON Biotechnology, Korea) according to the manufacturer's instructions. For each of the 8 SNPs in the four genes, ALOX5, ALOX5AP, PTGS2 and LTC4S, analyzed, pairs of forward and reverse primers were designed to amplify the genomic region surrounding the SNP of interest (Table 1). The polymerase chain reaction (PCR) was performed with 20 ng genomic DNA, 50 mM KCl, 10 mM Tris, 2 mM MgCl2, 1.25 pmol of each primer, 200 microM dNTPs, and 0.15 U Taq DNA polymerase (Perkin Elmer, Emeryville, CA, U.S.A.) in standard buffer provided by the manufacturer. After initial denaturation for 5 min at 95℃, a touch-down PCR (22) was undertaken with 10 cycles consisting of 1 min denaturation at 94℃, 1 min annealing at 54℃ and 2 min elongation at 72℃ followed by 35 cycles of 1 min at 94℃, 1 min at 45℃ and 2 min at 72℃. A final elongation step at 72℃ for 10 min terminated the program. Primer extension reactions were performed with the SNaPSHOT ddNTP primer extension kit (Applied Biosystems) as recommend by the manufacturer using extension probes as previously described (17).
###end p 14
###begin title 15
Data analysis
###end title 15
###begin p 16
###xml 97 98 97 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 684 686 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 431 439 <span type="species:ncbi:9606">patients</span>
###xml 560 567 <span type="species:ncbi:9606">patient</span>
Statistical analyses were completed using SPSS version 10 (SPSS Inc., Chicago, IL, U.S.A.) and a p-value <0.05 was considered to be significant. Allele frequencies were calculated for each polymorphic site by the allele counting method, and significant departures of genotype frequency from the Hardy-Weinberg equilibrium (HWE) at each polymorphic site were tested by chi-square analysis. Differences in genotype frequency between patients and controls were tested by Fisher's exact test. Differences in the mean value of the phenotypic characteristics within patient groups were compared using ANOVA and t-test. Haplotypes of ALOX5 were analyzed by using the Haploview version 2.05 (23).
###end p 16
###begin title 17
RESULTS
###end title 17
###begin p 18
###xml 54 61 54 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 124 125 124 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 173 174 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 27 39 <span type="species:ncbi:9606">participants</span>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 303 311 <span type="species:ncbi:9606">patients</span>
###xml 325 333 <span type="species:ncbi:9606">Patients</span>
###xml 485 493 <span type="species:ncbi:9606">Patients</span>
The characteristics of the participants were shown in Table 1. The three groups significantly differed with respect to age (p<0.01 for AIU vs. AIA) and prevalence of atopy (p<0.01 for AIU vs. NC and AIU vs. AIA) between AIU and other control groups. Seventy (77.8%) patients with AIU and 35 (43.8%) AIA patients were atopic. Patients with AIU were composed of 31 (30.7%) chronic urticaria exacerbated by ASA, 18 (17.8%) combined with angioedema and 4 (4.0%) combined with anaphylaxis. Patients with both AIA and AIU were excluded in this study.
###end p 18
###begin p 19
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5</italic>
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5AP</italic>
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTGS2</italic>
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTC4S</italic>
###xml 182 183 182 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 262 269 262 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 311 316 311 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5</italic>
###xml 526 527 526 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 584 585 584 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
We investigated 8 SNPs of ALOX5, ALOX5AP, PTGS2 and LTC4S in AIU compared to other control groups, AIA and NC. Genotype distributions of all loci were in Hardy-Weinberg equilibrium (p>0.05). Allele and genotype frequencies of each SNP in four genes are shown in Table 2. Of all SNPs tested, the polymorphism of ALOX5 at positions of -1708 G>A showed significant difference in genotype frequency between AIU and AIA; the frequency of minor genotype of ALOX5-1708G>A was significantly higher in AIU group compared to AIA group (p=0.01 in dominant model, OR=8.9, 95% CI=1.13-10.73). The p value remained significant after correction for multiple comparisons (Pc=0.045). For all other SNPs tested, there were no significant differences in allele and genotype frequencies among the three groups.
###end p 19
###begin p 20
###xml 233 240 231 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 501 502 499 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 687 688 685 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 788 795 786 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">Table 4</xref>
###xml 929 930 927 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 963 964 961 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1083 1088 1081 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5</italic>
###xml 107 114 <span type="species:ncbi:9606">patient</span>
Using Haploview program, haplotypes were constructed for 3 SNPs and the frequency of each haplotype in the patient groups was assessed. The frequency of five haplotypes of ALOX5 showing >/=1% frequency in the population was shown in Table 3. There were significant differences observed in the frequency of the ALOX5 haplotypes between the AIU group and AIA group; the frequency of ALOX5 ht1 [G-G-A] carrying major alleles of 3 SNPs in the AIU group was significantly lower than that in the AIA group (p=0.01, OR=0.541, 95% CI=0.339-0.865), but the frequencies of haplotypes carrying minor allele of ALOX5-1708G>A, ht2 [A-G-A] was significantly higher in AIU group compared to AIA group (p=0.05, OR=1.697, 95% CI=1.00-2.88). Analysis of the genotype distributions of the ALOX5 haplotypes (Table 4) also revealed that frequencies of genotype containing ht1 [G-G-A] and ht2 [A-G-A] were significantly different between AIA and AIU (p=0.01 in dominant model for ht1, p=0.02 in recessive model for ht2). However, there were no differences in allele, genotype, or haplotype frequencies of ALOX5 polymorphisms between the AIU group and the normal control. Haplotypic analysis of PTGS2 polymorphism was not undertaken due to the extremely low frequencies of the variant alleles.
###end p 20
###begin title 21
DISCUSSION
###end title 21
###begin p 22
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5</italic>
###xml 106 113 106 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5AP</italic>
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTGS2</italic>
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTC4S</italic>
In this study, we have investigated genetic association between polymorphisms of LT related genes (ALOX5, ALOX5AP, PTGS2 and LTC4S) and AIU in a Korean population.
###end p 22
###begin p 23
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5</italic>
###xml 172 173 172 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 527 532 527 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5</italic>
###xml 534 539 534 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTC4S</italic>
###xml 541 546 541 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTGS2</italic>
###xml 551 558 551 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5AP</italic>
Among 8 SNPs of four LT related genes, the polymorphism of ALOX5 at positions of -1708 G>A showed highly significant differences in genotype frequency between AIU and AIA (p=0.01). Furthermore, there were significant differences observed in the frequency of the ALOX5 haplotypes (ht1 and ht2) between the AIU group and AIA group. However there were no differences in allele, genotype, or haplotype frequencies in ALOX5 -1708 G>A between the AIU group and the normal control. In association study of 8 SNPs in LT related genes, ALOX5, LTC4S, PTGS2 and ALOX5AP with phenotypes (sex, age, atopy, tIgE), we could not find any significant difference.
###end p 23
###begin p 24
###xml 846 848 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 850 852 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 1060 1065 1060 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5</italic>
In our previous study, we found that an ALOX5-ht1 [G-C-G-A] was associated with AIA but not ASA-tolerant asthma; the frequency of the ALOX5-ht1 [G-C-G-A] carrying major alleles of these 3 SNPs in the AIA group was significantly higher than its frequency in the control group. In addition, consistent with the present study, significant differences in frequency of the ALOX5 polymorphism at positions of -1708G>A was also observed between the AIU group and the AIA group. The results of the present study however, suggested that unlike AIA, susceptibility to AIU is associated with minor genotype of ALOX5 -1708G>A. There was a significant difference in atopy frequency between the AIA and AIU groups. However this may be unlikely to influence the results as previous studies have not identified association of LT related polymorphism with atopy (24, 25). It may be possible that ALOX5 polymorphism may contribute to AIU susceptibility with odds ratio (OR) of 8.9 and 95% confidence interval (95% CI) of 1.13-70.73 relative to AIA. These results suggested that ALOX5, which catalyzes the first step in the formation of LT, has a differing contribution in two major clinical pathogenesis related to ASA-sensitivity.
###end p 24
###begin p 25
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 340 341 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
This study has several potential limitations. It is possible to observe a discordant result, oral tests were postitive but the bronchial tests were negative, according to the provocation route (26). Our limited power to detect modest effects may at least partially explain our modest evidence of association to ALOX5 SNP. While the minimum p-values we observed were modest, this is consistent with our expectations regarding common, complex conditions such as AIA and AIU.
###end p 25
###begin p 26
###xml 287 292 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5</italic>
In conclusion, we have shown that ALOX5 has a differing contribution in two major clinical pathogenesis related to ASA-sensitivity. Our studies suggested that ALOX5 may be a potentially important gene in AIU susceptibility in the Korean population, and that promoter polymorphism of the ALOX5 gene might contribute to AIU susceptibility relative to AIA. Further studies will be needed to confirm functional effect of the ALOX5 -1708 G>A on the pathogenic mechanism of AIU.
###end p 26
###begin p 27
###xml 72 119 72 119 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ministry of Health &amp; Welfare, Republic of Korea</funding-source>
###xml 121 144 121 144 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">01-PJ10-PG6-01GN14-0002</award-id>
This study was supported by a grant of the Korea Health 21 R&D project. Ministry of Health & Welfare, Republic of Korea (01-PJ10-PG6-01GN14-0002).
###end p 27
###begin article-title 28
Aspirin sensitivity and urticaria
###end article-title 28
###begin article-title 29
Hypersensitivity to aspirin: Common eicosanoid alterations in urticaria and asthma
###end article-title 29
###begin article-title 30
Anaphylactoid reactions due to nonsteroidal antiinflammatory drugs: clinical and cross-reactivity studies
###end article-title 30
###begin article-title 31
Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects
###end article-title 31
###begin article-title 32
Urinary leukotriene E4 in bronchial asthma
###end article-title 32
###begin article-title 33
Antileukotriene therapy. Future directions
###end article-title 33
###begin article-title 34
Treatment of asthma with drugs modifying the leukotriene pathway
###end article-title 34
###begin article-title 35
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Reactions to aspirin and food additives in patients with chronic urticaria, including the physical urticarias
###end article-title 35
###begin article-title 36
Sensitivity to aspirin and nonsteroidal anti-inflammatory drugs
###end article-title 36
###begin article-title 37
###xml 108 113 <span type="species:ncbi:9606">human</span>
Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases
###end article-title 37
###begin article-title 38
The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study
###end article-title 38
###begin article-title 39
###xml 160 168 <span type="species:ncbi:9606">patients</span>
Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid
###end article-title 39
###begin article-title 40
Successful treatment of chronic urticaria with leukotriene antagonists
###end article-title 40
###begin article-title 41
Pretreatment with montelukast blocks NSAID-induced urticaria and angioedema
###end article-title 41
###begin article-title 42
Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs
###end article-title 42
###begin article-title 43
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions
###end article-title 43
###begin article-title 44
Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase
###end article-title 44
###begin article-title 45
Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma
###end article-title 45
###begin article-title 46
Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma
###end article-title 46
###begin article-title 47
Cutaneous reactions to aspirin and nonsteroidal anti-inflammatory drugs
###end article-title 47
###begin article-title 48
###xml 107 115 <span type="species:ncbi:9606">patients</span>
Early and late onset asthmatic responses following lysineaspirin inhalation in aspirin-sensitive asthmatic patients
###end article-title 48
###begin article-title 49
###xml 67 84 <span type="species:ncbi:10788">canine parvovirus</span>
###xml 89 115 <span type="species:ncbi:10786">feline panleukopenia virus</span>
A simple touch-down polymerase chain reaction for the detection of canine parvovirus and feline panleukopenia virus in feces
###end article-title 49
###begin article-title 50
Haploview: analysis and visualization of LD and haplotype maps
###end article-title 50
###begin article-title 51
Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population
###end article-title 51
###begin article-title 52
Allelic association and functional studies of promoter polymorphism in the Leukotriene C4 synthase gene (LTC4S) in asthma
###end article-title 52
###begin article-title 53
Oral and bronchial provocation tests with aspirin for diagnosis of aspirininduced asthma
###end article-title 53
###begin p 54
Clinical characteristics of the study subjects
###end p 54
###begin p 55
AIU, ASA-intolerant urticaria; AIA, ASA-intolerant asthma; NC, normal controls; NA, not applicable.
###end p 55
###begin p 56
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 23 29 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 29 30 24 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
*p<0.01 (AIU vs. AIA). daggerp<0.01 (AIU vs. AIA and AIU vs. NC).
###end p 56
###begin p 57
Allele and genotype frequencies of the SNPs in the candidate genes
###end p 57
###begin p 58
###xml 178 179 178 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 184 185 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
AIU, ASA-intolerant urticaria; AIA, ASA-intolerant asthma; NC, normal controls; n, number of patients; q, minor allele frequency. R, arginine; H, histidine; NS, not significant. *Each p value was calculated with co-dominant, dominant and recessive models.
###end p 58
###begin p 59
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5</italic>
Haplotype frequencies of ALOX5 gene. The haplotype of ALOX5 is in order of -1708G>A, 270 G>A, 1728 A>G
###end p 59
###begin p 60
AIU, ASA-intolerant urticaria; AIA, ASA-intolerant asthma; NC, normal controls; Ht,haplotype; N, number of chromosomes.
###end p 60
###begin p 61
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
*Minor alleles are given in bold.
###end p 61
###begin p 62
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALOX5</italic>
Genotype distributions of ALOX5 haplotypes
###end p 62
###begin p 63
###xml 0 6 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
daggerAIU, ASA-intolerant urticaria; AIA, ASA-intolerant asthma; NC, normal controls; Ht, haplotype.
###end p 63
###begin p 64
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 6 7 6 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
*Each p value was calculated with co-dominant, dominant and recessive models.
###end p 64

